{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:51:50Z","timestamp":1791402710675,"version":"4.3.3"},"reference-count":139,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The orexin (hypocretin) system plays a central role in regulating the sleep\u2013wake cycle through two neuropeptides, orexin-A and orexin-B, which act on OX1R and OX2R receptors. Emerging evidence links heightened orexin signaling with the pathophysiology of chronic insomnia. This review outlines the neurobiology of the orexinergic system, compares the pharmacological profile of dual orexin receptor antagonists (DORAs) to traditional GABAergic hypnotics, and evaluates the clinical efficacy and safety of Suvorexant, Lemborexant, and Daridorexant. DORAs function by selectively dampening orexin-driven arousal, thereby facilitating sleep onset and maintenance without disrupting natural sleep architecture. Clinical trials have shown that these agents significantly reduce sleep latency and enhance sleep continuity, with a favorable side effect profile. Overall, DORAs represent a distinct and clinically advantageous option for insomnia treatment, with growing interest in their potential utility across mood, anxiety, and neurodegenerative disorders.<\/jats:p>","DOI":"10.3390\/ijms26178700","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:27:12Z","timestamp":1757500032000},"page":"8700","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Targeting the Orexin System in the Pharmacological Management of Insomnia and Other Diseases: Suvorexant, Lemborexant, Daridorexant, and Novel Experimental Agents"],"prefix":"10.3390","volume":"26","author":[{"given":"Kacper","family":"\u017be\u0142abowski","sequence":"first","affiliation":[{"name":"Scientific Society for Psychopharmacology, Department of Forensic Medicine, Wroclaw Medical University, 4 J. Mikulicza-Radeckiego Street, 50345 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktor","family":"Petrov","sequence":"additional","affiliation":[{"name":"Scientific Society for Psychopharmacology, Department of Forensic Medicine, Wroclaw Medical University, 4 J. Mikulicza-Radeckiego Street, 50345 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4595-7748","authenticated-orcid":false,"given":"Kacper","family":"Wojtysiak","sequence":"additional","affiliation":[{"name":"Scientific Society for Psychopharmacology, Department of Forensic Medicine, Wroclaw Medical University, 4 J. Mikulicza-Radeckiego Street, 50345 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0316-4907","authenticated-orcid":false,"given":"Zuzanna","family":"Ratka","sequence":"additional","affiliation":[{"name":"Scientific Society for Psychopharmacology, Department of Forensic Medicine, Wroclaw Medical University, 4 J. Mikulicza-Radeckiego Street, 50345 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2157-103X","authenticated-orcid":false,"given":"Kamil","family":"Biedka","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pathophysiology, Division of Pathophysiology, Wroclaw Medical University, Chalubinskiego 10, 50368 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8752-2321","authenticated-orcid":false,"given":"Micha\u0142","family":"Weso\u0142owski","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pathophysiology, Division of Pathophysiology, Wroclaw Medical University, Chalubinskiego 10, 50368 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Fus","sequence":"additional","affiliation":[{"name":"Scientific Society for Psychopharmacology, Department of Forensic Medicine, Wroclaw Medical University, 4 J. Mikulicza-Radeckiego Street, 50345 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9150-3768","authenticated-orcid":false,"given":"Dawid","family":"\u015alebioda","sequence":"additional","affiliation":[{"name":"Scientific Society for Psychopharmacology, Department of Forensic Medicine, Wroclaw Medical University, 4 J. Mikulicza-Radeckiego Street, 50345 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malwina","family":"Rusinek","sequence":"additional","affiliation":[{"name":"Scientific Society for Psychopharmacology, Department of Forensic Medicine, Wroclaw Medical University, 4 J. Mikulicza-Radeckiego Street, 50345 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8925-3260","authenticated-orcid":false,"given":"Maria","family":"Sterkowicz","sequence":"additional","affiliation":[{"name":"Scientific Society for Psychopharmacology, Department of Forensic Medicine, Wroclaw Medical University, 4 J. Mikulicza-Radeckiego Street, 50345 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0612-6280","authenticated-orcid":false,"given":"Izabela","family":"Radzka","sequence":"additional","affiliation":[{"name":"Scientific Society for Psychopharmacology, Department of Forensic Medicine, Wroclaw Medical University, 4 J. Mikulicza-Radeckiego Street, 50345 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Ch\u0142opa\u015b-Konowa\u0142ek","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine, Division of Molecular Techniques, Faculty of Medicine, Wroclaw Medical University, Sklodowskiej-Curie 52, 50369 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000514960","article-title":"Sleep, Orexin and Cognition","volume":"45","author":"Toor","year":"2021","journal-title":"Front. Neurol. Neurosci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e13665","DOI":"10.1111\/jsr.13665","article-title":"The orexin story, sleep and sleep disturbances","volume":"31","author":"Pizza","year":"2022","journal-title":"J. Sleep Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/pharmrev.123.000953","article-title":"International Union of Basic and Clinical Pharmacology CXIV: Orexin Receptor Function, Nomenclature and Pharmacology","volume":"76","author":"Kukkonen","year":"2024","journal-title":"Pharmacol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Zhou, M., and Tang, S. (2022). Effect of a dual orexin receptor antagonist on Alzheimer\u2019s disease: Sleep disorders and cognition. Front. Med., 9.","DOI":"10.3389\/fmed.2022.984227"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e13825","DOI":"10.1111\/jsr.13825","article-title":"Current models of insomnia disorder: A theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment","volume":"32","author":"Palagini","year":"2023","journal-title":"J. Sleep Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","article-title":"Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders","volume":"16","author":"Muehlan","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/15500594221090067","article-title":"The Role of Sleep in Cognitive Function: The Value of a Good Night\u2019s Rest","volume":"54","author":"Gilley","year":"2023","journal-title":"Clin. EEG Neurosci."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhou, L., Kong, J., Li, X., and Ren, Q. (2023). Sex differences in the effects of sleep disorders on cognitive dysfunction. Neurosci. Biobehav. Rev., 146.","DOI":"10.1016\/j.neubiorev.2023.105067"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101472","DOI":"10.1016\/j.smrv.2021.101472","article-title":"Sleep and human cognitive development","volume":"57","author":"Mason","year":"2021","journal-title":"Sleep Med. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41562-024-01827-6","article-title":"Individual sleep need is flexible and dynamically related to cognitive function","volume":"8","author":"Fjell","year":"2024","journal-title":"Nat. Hum. Behav."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e13868","DOI":"10.1111\/jsr.13868","article-title":"Potential genetic and epigenetic mechanisms in insomnia: A systematic review","volume":"32","author":"Palagini","year":"2023","journal-title":"J. Sleep Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e13628","DOI":"10.1111\/jsr.13628","article-title":"Sleep, insomnia and mental health","volume":"31","author":"Palagini","year":"2022","journal-title":"J. Sleep Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e13604","DOI":"10.1111\/jsr.13604","article-title":"Insomnia disorder: State of the science and challenges for the future","volume":"31","author":"Riemann","year":"2022","journal-title":"J. Sleep Res."},{"key":"ref_14","unstructured":"McNamara, S., Spurling, B.C., and Bollu, P.C. (2025, August 28). Chronic Insomnia, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526136\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"ITC33","DOI":"10.7326\/AITC202103160","article-title":"Insomnia","volume":"174","author":"Sutton","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101456","DOI":"10.1016\/j.smrv.2021.101456","article-title":"The association of insomnia disorder characterised by objective short sleep duration with hypertension, diabetes and body mass index: A systematic review and meta-analysis","volume":"59","author":"Johnson","year":"2021","journal-title":"Sleep Med. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201912-2330OC","article-title":"Associations of Sleep-disordered Breathing and Insomnia with Incident Hypertension and Diabetes. The Hispanic Community Health Study\/Study of Latinos","volume":"203","author":"Li","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.sleep.2024.01.023","article-title":"Prevalence of insomnia and associations with depression, anxiety among adults in guangdong, China: A large-scale cross-sectional study","volume":"115","author":"Shan","year":"2024","journal-title":"Sleep Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.sleep.2022.12.005","article-title":"Insomnia, depression, and anxiety symptoms interact and individually impact functioning: A network and relative importance analysis in the context of insomnia","volume":"101","author":"Bard","year":"2023","journal-title":"Sleep Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e14252","DOI":"10.1111\/jsr.14252","article-title":"Chronic insomnia, REM sleep instability and emotional dysregulation: A pathway to anxiety and depression?","volume":"34","author":"Riemann","year":"2025","journal-title":"J. Sleep Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Morin, C.M., Bertisch, S.M., Pelayo, R., Watson, N.F., Winkelman, J.W., Zee, P.C., and Krystal, A.D. (2023). What Should Be the Focus of Treatment When Insomnia Disorder Is Comorbid with Depression or Anxiety Disorder?. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051975"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jad.2022.11.021","article-title":"Insomnia is a key risk factor for persistent anxiety and depressive symptoms: A 12-month longitudinal cohort study during the COVID-19 pandemic","volume":"322","author":"Meaklim","year":"2023","journal-title":"J. Affect. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101282","DOI":"10.1016\/j.smrv.2020.101282","article-title":"Sleep in the anxiety-related disorders: A meta-analysis of subjective and objective research","volume":"51","author":"Cox","year":"2020","journal-title":"Sleep Med. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41386-019-0486-5","article-title":"Sleep disturbance in PTSD and other anxiety-related disorders: An updated review of clinical features, physiological charac-teristics, and psychological and neurobiological mechanisms","volume":"45","author":"Richards","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000517329","article-title":"The Many Faces of Sleep Disorders in Post-Traumatic Stress Disorder: An Update on Clinical Features and Treatment","volume":"81","author":"Weber","year":"2022","journal-title":"Neuropsychobiology"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lancel, M., van Marle, H.J.F., Van Veen, M.M., and van Schagen, A.M. (2021). Disturbed Sleep in PTSD: Thinking Beyond Nightmares. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.767760"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1017\/S2045796021000810","article-title":"Sleep disturbance and psychiatric disorders: A bidirectional Mendelian randomisation study","volume":"31","author":"Sun","year":"2022","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.62641\/aep.v52i2.1659","article-title":"Orexinergic Receptor Antagonists as a New Therapeutic Target to Overcome Limitations of Current Pharmacological Treatment of Insomnia Disorder","volume":"52","author":"Ruiz","year":"2024","journal-title":"Actas Esp. Psiquiatr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101746","DOI":"10.1016\/j.smrv.2023.101746","article-title":"Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis","volume":"68","author":"Yue","year":"2023","journal-title":"Sleep Med. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.neubiorev.2021.09.035","article-title":"A network meta-analysis of the long- and short-term efficacy of sleep medicines in adults and older adults","volume":"131","author":"Wang","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e13902","DOI":"10.1111\/jsr.13902","article-title":"The orexin story and orexin receptor antagonists for the treatment of insomnia","volume":"32","author":"Muehlan","year":"2023","journal-title":"J. Sleep Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/10600280211008492","article-title":"Review of the Efficacy and Safety of Lemborexant, a Dual Receptor Orexin Antagonist (DORA), in the Treatment of Adults with Insomnia Disorder","volume":"56","author":"Waters","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40263-023-01020-9","article-title":"Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem","volume":"37","author":"Scammell","year":"2023","journal-title":"CNS Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s40120-024-00622-9","article-title":"Efficacy of Lemborexant in Adults\u2009\u2265\u200965 Years of Age with Insomnia Disorder","volume":"13","author":"Arnold","year":"2024","journal-title":"Neurol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40266-022-00977-4","article-title":"Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial","volume":"39","author":"Fietze","year":"2022","journal-title":"Drugs Aging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.sleep.2024.12.023","article-title":"Effect of lemborexant on sleep architecture in participants with insomnia disorder and mild obstructive sleep apnea","volume":"127","author":"Kushida","year":"2025","journal-title":"Sleep Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Boof, M.-L., Dingemanse, J., Lederer, K., Fietze, I., and Ufer, M. (2025, August 02). Effect of the New Dual Orexin Receptor Antagonist Daridorexant on Nighttime Respiratory Function and Sleep in Patients with Mild and Moderate Obstructive Sleep Apnea|SLEEP|Oxford Academic. Available online: https:\/\/academic.oup.com\/sleep\/article\/44\/6\/zsaa275\/6030922.","DOI":"10.1093\/sleep\/zsaa275"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Jiang, M., Li, H., and Kong, L. (2024). Data mining and safety analysis of dual orexin receptor antagonists (DORAs): A real-world pharmacovigilance study based on the FAERS database. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1436405"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"zsaa123","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: Results from the phase 3 randomized clinical trial SUNRISE 2","volume":"43","author":"Yardley","year":"2020","journal-title":"Sleep"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40266-024-01135-8","article-title":"Efficacy and safety of insomnia treatment with lemborexant in older adults: Analyses from three clinical trials","volume":"41","author":"Gotfried","year":"2024","journal-title":"Drugs Aging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/med.21959","article-title":"Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders","volume":"43","author":"Bonifazi","year":"2023","journal-title":"Med. Res. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"109815","DOI":"10.1016\/j.neuropharm.2023.109815","article-title":"Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities","volume":"245","author":"Carpi","year":"2024","journal-title":"Neuropharmacology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1093\/sleep\/zsab072.058","article-title":"059 Daridorexant: A dual, equipotent, and insurmountable antagonist of both orexin-1 and orexin-2 receptors","volume":"44","author":"Grandjean","year":"2021","journal-title":"Sleep"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"146085","DOI":"10.1016\/j.brainres.2018.12.036","article-title":"Orexin\/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy","volume":"1731","author":"Summers","year":"2020","journal-title":"Brain Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2018.12.008","article-title":"Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review","volume":"92","author":"Shariq","year":"2019","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41398-020-00937-9","article-title":"Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans","volume":"10","author":"Salvadore","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.brainresbull.2022.05.006","article-title":"Sleep-wake and arousal dysfunctions in post-traumatic stress disorder: Role of orexin systems","volume":"186","author":"Kaplan","year":"2022","journal-title":"Brain Res. Bull."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Lawrence, A.J., and de Lecea, L. (2017). Orexin\/Hypocretin and Organizing Principles for a Diversity of Wake-Promoting Neurons in the Brain. Behavioral Neuroscience of Orexin\/Hypocretin, Springer International Publishing.","DOI":"10.1007\/978-3-319-57535-3"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12079-022-00700-3","article-title":"A molecular network map of orexin-orexin receptor signaling system","volume":"17","author":"Chatterjee","year":"2023","journal-title":"J. Cell Commun. Signal."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1038\/s41467-022-30601-3","article-title":"Molecular mechanism of the wake-promoting agent TAK-925","volume":"13","author":"Yin","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"118401","DOI":"10.1016\/j.jep.2024.118401","article-title":"A comprehensive study on the regulation of Compound Zaoren Granules on cAMP\/CREB signaling pathway and metabolic disorder in CUMS-PCPA induced insomnia rats","volume":"332","author":"Wang","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Cao, X.-L., Peng, X.-M., Li, G.-B., Ding, W.-S., Wang, K.-Z., Wang, X.-L., Xiong, Y.-Y., Xiong, W.-J., Li, F., and Song, M. (2023). Chaihu-Longgu-Muli decoction improves sleep disorders by restoring orexin-A function in CKD mice. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1206353"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"118907","DOI":"10.1016\/j.jep.2024.118907","article-title":"Mechanism of action of Panax ginseng alcohol extract based on orexin-mediated autophagy in the treatment of sleep and cognition in aged sleep-deprived rats","volume":"337","author":"Lin","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3949\/ccjm.92a.24073","article-title":"Insomnia in older adults: A review of treatment options","volume":"92","author":"Chaplin","year":"2025","journal-title":"Cleve. Clin. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Porwal, A., Yadav, Y.C., Pathak, K., and Yadav, R. (2021). An Update on Assessment, Therapeutic Management, and Patents on Insomnia. BioMed Res. Int., 2021.","DOI":"10.1155\/2021\/6068952"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e14302","DOI":"10.1111\/jsr.14302","article-title":"Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: Results from phase 1 and 2 studies","volume":"34","author":"Uchiyama","year":"2025","journal-title":"J. Sleep Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/JCP.0000000000001561","article-title":"Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared with Zolpidem and Suvorexant in Recreational Sedative Users","volume":"42","author":"Landry","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_58","first-page":"67898","article-title":"Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia","volume":"10","author":"Han","year":"2022","journal-title":"Health Psychol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e12506","DOI":"10.1002\/npr2.12506","article-title":"Characteristics of psychiatric patients with nightmares after suvorexant administration: A retrospective study","volume":"45","author":"Yasuda","year":"2025","journal-title":"Neuropsychopharmacol. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e1918254","DOI":"10.1001\/jamanetworkopen.2019.18254","article-title":"Comparison of Lemborexant with Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults with Insomnia Disorder: A Phase 3 Randomized Clinical Trial","volume":"2","author":"Rosenberg","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Katzman, M.A., and Katzman, M.P. (2022). Neurobiology of the Orexin System and Its Potential Role in the Regulation of Hedonic Tone. Brain Sci., 12.","DOI":"10.3390\/brainsci12020150"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"108013","DOI":"10.1016\/j.neuropharm.2020.108013","article-title":"Recent perspectives on orexin\/hypocretin promotion of addiction-related behaviors","volume":"168","author":"Hopf","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Yamamoto, H., Nagumo, Y., Ishikawa, Y., Irukayama-Tomobe, Y., Namekawa, Y., Nemoto, T., Tanaka, H., Takahashi, G., Tokuda, A., and Saitoh, T. (2022). OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep\/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0271901"},{"key":"ref_64","unstructured":"Sun, Y., Tisdale, R.K., and Kilduff, T.S. (2025, August 02). Hypocretin\/Orexin Receptor Pharmacology and Sleep Phases. Available online: https:\/\/karger.com\/books\/book\/380\/chapter\/5563796\/Hypocretin-Orexin-Receptor-Pharmacology-and-Sleep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"145922","DOI":"10.1016\/j.brainres.2018.08.025","article-title":"Therapeutics development for addiction: Orexin-1 receptor antagonists","volume":"1731","author":"Perrey","year":"2020","journal-title":"Brain Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000514965","article-title":"The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System","volume":"45","author":"Fragale","year":"2021","journal-title":"Front. Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12264-019-00447-9","article-title":"Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders","volume":"36","author":"Han","year":"2020","journal-title":"Neurosci. Bull."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Yukitake, H., Fujimoto, T., Ishikawa, T., Suzuki, A., Shimizu, Y., Rikimaru, K., Ito, M., Suzuki, M., and Kimura, H. (2019). TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice. Pharmacol. Biochem. Behav., 187.","DOI":"10.1016\/j.pbb.2019.172794"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/eat.24181","article-title":"Evaluating the efficacy of the selective orexin 1 receptor antagonist nivasorexant in an animal model of binge-eating disorder","volume":"57","author":"Steiner","year":"2024","journal-title":"Int. J. Eat. Disord."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"171007","DOI":"10.1016\/j.peptides.2023.171007","article-title":"The role of orexin neuron activity in sleep\/wakefulness regulation","volume":"165","author":"Hung","year":"2023","journal-title":"Peptides"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"149408","DOI":"10.1016\/j.brainres.2024.149408","article-title":"The mechanism of different orexin\/hypocretin neuronal projections in wakefulness and sleep","volume":"1850","author":"Li","year":"2025","journal-title":"Brain Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"107993","DOI":"10.1016\/j.neuropharm.2020.107993","article-title":"The hypocretin (orexin) system: From a neural circuitry perspective","volume":"167","author":"Li","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Soya, S., and Sakurai, T. (2020). Evolution of Orexin Neuropeptide System: Structure and Function. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.00691"},{"key":"ref_74","unstructured":"Sakurai, T., Saito, Y.C., and Yanagisawa, M. (2025, August 02). Interaction between Orexin Neurons and Monoaminergic Systems. Available online: https:\/\/karger.com\/books\/book\/380\/chapter\/5563735\/Interaction-between-Orexin-Neurons-and."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Saito, Y.C., Tsujino, N., Abe, M., Yamazaki, M., Sakimura, K., and Sakurai, T. (2018). Serotonergic Input to Orexin Neurons Plays a Role in Maintaining Wakefulness and REM Sleep Architecture. Front. Neurosci., 12.","DOI":"10.3389\/fnins.2018.00892"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e13631","DOI":"10.1111\/jsr.13631","article-title":"Narcolepsy","volume":"31","author":"Barateau","year":"2022","journal-title":"J. Sleep Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","article-title":"Narcolepsy\u2014clinical spectrum, aetiopathophysiology, diagnosis and treatment","volume":"15","author":"Bassetti","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1002\/acn3.50908","article-title":"Children with Narcolepsy type 1 have increased T-cell responses to orexins","volume":"6","author":"Cogswell","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"zsaa055","DOI":"10.1093\/sleep\/zsaa055","article-title":"Narcolepsy type 1: What have we learned from immunology?","volume":"43","author":"Kornum","year":"2020","journal-title":"Sleep"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","article-title":"The neurobiological basis of narcolepsy","volume":"20","author":"Mahoney","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Sochal, M., Ditmer, M., Turkiewicz, S., Karuga, F.F., Bia\u0142asiewicz, P., and Gabryelska, A. (2024). The effect of sleep and its restriction on selected inflammatory parameters. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-68498-1"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Couvineau, A., Voisin, T., Nicole, P., Gratio, V., Abad, C., and Tan, Y.-V. (2019). Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00709"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/pr.58.1.4","article-title":"Orexins in the Regulation of the Hypothalamic-Pituitary-Adrenal Axis","volume":"58","author":"Spinazzi","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Dong, Y.-J., Jiang, N.-H., Zhan, L.-H., Teng, X., Fang, X., Lin, M.-Q., Xie, Z.-Y., Luo, R., Li, L.-Z., and Li, B. (2021). Soporific effect of modified Suanzaoren Decoction on mice models of insomnia by regulating Orexin-A and HPA axis homeostasis. Biomed. Pharmacother., 143.","DOI":"10.1016\/j.biopha.2021.112141"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Steward, T., Mestre-Bach, G., Granero, R., S\u00e1nchez, I., Riesco, N., Vintr\u00f3-Alcaraz, C., Sauchelli, S., Jim\u00e9nez-Murcia, S., Ag\u00fcera, Z., and Fern\u00e1ndez-Garc\u00eda, J.C. (2019). Reduced Plasma Orexin-A Concentrations are Associated with Cognitive Deficits in Anorexia Nervosa. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-44450-6"},{"key":"ref_86","first-page":"4110","article-title":"Correlation of serum Orexin-A level with cognitive function and serum inflammatory cytokines in epileptic patients","volume":"15","author":"Li","year":"2023","journal-title":"Am. J. Transl. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.neurobiolaging.2016.01.007","article-title":"Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer\u2019s disease","volume":"40","author":"Liguori","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neurobiolaging.2023.01.008","article-title":"Orexin-A aggravates cognitive deficits in 3xTg-AD mice by exacerbating synaptic plasticity impairment and affecting amyloid \u03b2 metabolism","volume":"124","author":"Li","year":"2023","journal-title":"Neurobiol. Aging"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Wang, Q., Cao, F., and Wu, Y. (2021). Orexinergic System in Neurodegenerative Diseases. Front. Aging Neurosci., 13.","DOI":"10.3389\/fnagi.2021.713201"},{"key":"ref_90","first-page":"1757","article-title":"Alzheimer\u2019s disease with sleep insufficiency: A cross-sectional study on correlations among clinical characteristics, orexin, its receptors, and the blood-brain barrier","volume":"18","author":"Guo","year":"2022","journal-title":"Neural Regen. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.sleep.2021.07.007","article-title":"Cerebrospinal fluid orexin in Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"85","author":"Treu","year":"2021","journal-title":"Sleep Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ana.26641","article-title":"Suvorexant Acutely Decreases Tau Phosphorylation and A\u03b2 in the Human CNS","volume":"94","author":"Lucey","year":"2023","journal-title":"Ann. Neurol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Wang, C., Wang, Q., Ji, B., Pan, Y., Xu, C., Cheng, B., Bai, B., and Chen, J. (2018). The Orexin\/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases. Front. Mol. Neurosci., 11.","DOI":"10.3389\/fnmol.2018.00220"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e2112225119","DOI":"10.1073\/pnas.2112225119","article-title":"The evolutionarily conserved miRNA-137 targets the neuropeptide hypocretin\/orexin and modulates the wake to sleep ratio","volume":"119","author":"Holm","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/NSS.S201994","article-title":"Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations","volume":"15","author":"Mogavero","year":"2023","journal-title":"Nat. Sci. Sleep"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: A phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: Results from two multicentre, randomised, dou-ble-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40261-019-00764-x","article-title":"Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects","volume":"39","author":"Wrishko","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"ref_99","first-page":"249","article-title":"The interim report about the drug use\u2014Results survey of orexinergic receptor antagonist, Belsomra, in patients with insomnia","volume":"11","author":"Asai","year":"2017","journal-title":"Jpn. J. Sleep Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40268-018-0256-6","article-title":"Suvorexant (Belsomra\u00ae Tablets 10, 15, and 20 mg): Japanese Drug-Use Results Survey","volume":"19","author":"Asai","year":"2019","journal-title":"Drugs RD"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"A59","DOI":"10.1016\/j.jval.2016.03.177","article-title":"Psychiatric Safety Profile Of Suvorexant, A First-In-Class Orexin Receptor Antagonist","volume":"19","author":"Ali","year":"2016","journal-title":"Value Health"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e13371","DOI":"10.2196\/13371","article-title":"Adverse Events Due to Insomnia Drugs Reported in a Regulatory Database and Online Patient Reviews: Comparative Study","volume":"21","author":"Borchert","year":"2019","journal-title":"J. Med. Internet Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e970","DOI":"10.4088\/JCP.16m11194","article-title":"Preventive Effects of Suvorexant on Delirium: A Randomized Placebo-Controlled Trial","volume":"78","author":"Hatta","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/npr2.12205","article-title":"Evidence-based insomnia treatment strategy using novel orexin antagonists: A review","volume":"41","author":"Kishi","year":"2021","journal-title":"Neuropsychopharmacol. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpsychires.2020.05.025","article-title":"Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis","volume":"128","author":"Kishi","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/cpdd.817","article-title":"Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults","volume":"10","author":"Landry","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e00758","DOI":"10.1002\/prp2.758","article-title":"Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant","volume":"9","author":"Dayal","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/02698811221080459","article-title":"Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study","volume":"36","author":"Landry","year":"2022","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5664\/jcsm.10788","article-title":"A randomized, double-blind, placebo-controlled, crossover study of respiratory safety of lemborexant in moderate to severe obstructive sleep apnea","volume":"20","author":"Cheng","year":"2024","journal-title":"J. Clin. Sleep Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.sleep.2021.01.048","article-title":"Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: Results from a phase 3 randomized clinical trial","volume":"80","author":"Yardley","year":"2021","journal-title":"Sleep Med."},{"key":"ref_111","unstructured":"Terada, T., Hirayama, T., Sadahiro, R., Wada, S., Nakahara, R., and Matsuoka, H. (2025, August 02). Pilot Study of Lemborexant for Insomnia in Cancer Patients with Delirium|Journal of Palliative Medicine. Available online: https:\/\/www.liebertpub.com\/doi\/10.1089\/jpm.2021.0509."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in Patients with Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Xue, T., Wu, X., Li, J., Chen, S., Wang, Z., Tan, X., Wang, Z., and Zhang, J. (2023). Different doses of dual orexin receptor antagonists in primary insomnia: A Bayesian network analysis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1175372"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.5664\/jcsm.6800","article-title":"Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study","volume":"13","author":"Murphy","year":"2017","journal-title":"J. Clin. Sleep Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","article-title":"Nonclinical pharmacology of daridorexant: A new dual orexin receptor antagonist for the treatment of insomnia","volume":"238","author":"Roch","year":"2021","journal-title":"Psychopharmacology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: First Approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40263-022-00980-8","article-title":"Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder","volume":"37","author":"Kunz","year":"2023","journal-title":"CNS Drugs"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1111\/cts.13079","article-title":"Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment","volume":"14","author":"Berger","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cpt.2592","article-title":"Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator","volume":"111","author":"Muehlan","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40263-023-00987-9","article-title":"Daridorexant in Insomnia Disorder: A Profile of Its Use","volume":"37","author":"Nie","year":"2023","journal-title":"CNS Drugs"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.sleep.2024.07.036","article-title":"Long-term safety and efficacy of daridorexant in Japanese patients with insomnia disorder","volume":"122","author":"Uchimura","year":"2024","journal-title":"Sleep Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/02698811241293997","article-title":"Nighttime safety of daridorexant: Evaluation of responsiveness to an external noise stimulus, postural stability, walking, and cognitive function","volume":"39","author":"Magliocca","year":"2025","journal-title":"J. Psychopharmacol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/cmdc.202000453","article-title":"The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders","volume":"15","author":"Boss","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/YIC.0000000000000552","article-title":"The potential use of daridorexant in eating disorders: Beyond the treatment of insomnia?","volume":"40","author":"Caldiroli","year":"2025","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/YIC.0000000000000488","article-title":"Clinical specificity profile for novel rapid acting antidepressant drugs","volume":"38","author":"Scala","year":"2023","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s00213-022-06089-6","article-title":"Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: A randomized, double-blind, placebo-controlled phase 2 study","volume":"239","author":"Uchiyama","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.2147\/DDDT.S501111","article-title":"Pharmacokinetics, Pharmacodynamic, Safety and Tolerability of Fazamorexant, a Novel Dual Orexin Receptor Antagonist: Report of the First-in-Human Study","volume":"19","author":"Ni","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/ALN.0000000000005375","article-title":"TAK-925 (Danavorexton), an Orexin Receptor 2 Agonist, Reduces Opioid-induced Respiratory Depression and Sedation Without Affecting Analgesia in Healthy Men","volume":"142","author":"Dahan","year":"2025","journal-title":"Anesthesiology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e6231","DOI":"10.1136\/bmj.e6231","article-title":"Benzodiazepine use and risk of dementia: Prospective population based study","volume":"345","author":"Bazin","year":"2012","journal-title":"BMJ"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bcp.14180","article-title":"Hypnotics with novel modes of action","volume":"86","author":"Hoyer","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"zsab068","DOI":"10.1093\/sleep\/zsab068","article-title":"Manipulation of rapid eye movement sleep via orexin and GABAA receptor modulators differentially affects fear extinction in mice: Effect of stable versus disrupted circadian rhythm","volume":"44","author":"Clark","year":"2021","journal-title":"Sleep"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/ggi.14600","article-title":"Association between the type of hypnotic drug and in-hospital fractures in older patients with neurocognitive disorders: A case-control study using a nationwide database","volume":"23","author":"Matsumoto","year":"2023","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1017\/S0033291722001854","article-title":"Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: A model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents","volume":"52","author":"Ikeda","year":"2022","journal-title":"Psychol. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"101351","DOI":"10.1016\/j.smrv.2020.101351","article-title":"Economic evaluation of cognitive behavioural therapy for insomnia (CBT-I) for improving health outcomes in adult populations: A systematic review","volume":"54","author":"Natsky","year":"2020","journal-title":"Sleep Med. Rev."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.5665\/sleep.1978","article-title":"ASL Imaging of Brain Function Changes During Sleep Restriction","volume":"35","author":"Rao","year":"2012","journal-title":"Sleep"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.watres.2011.10.056","article-title":"Environmental occurrence, fate and transformation of benzodiazepines in water treatment","volume":"46","author":"Kosjek","year":"2012","journal-title":"Water Res."},{"key":"ref_137","first-page":"241","article-title":"Lemborexant (Dayvigo) for the Treatment of Insomnia","volume":"103","author":"Rhodes","year":"2021","journal-title":"Am. Fam. Physician"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s41669-025-00567-1","article-title":"Cost-Effectiveness Analysis of Daridorexant for the Pharmacological Treatment of Chronic Insomnia Disorder in Adults","volume":"9","author":"Briggs","year":"2025","journal-title":"PharmacoEconomics Open"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1093\/sleep\/zsab072.057","article-title":"058 The interactions of Sleep, Heart Rate Variability and Aging on an Emotional Directed Forgetting Memory Task","volume":"44","author":"Sattari","year":"2021","journal-title":"Sleep"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8700\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:41:22Z","timestamp":1760035282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":139,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26178700"],"URL":"https:\/\/doi.org\/10.3390\/ijms26178700","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,6]]}}}